GlassScriptPhysician profile
Benjamin R Gilliland
NPI 1073967238
$8,253.85
in general payments reported to CMS, 2019-2025
38 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $970 · 2021: $1,369 · 2022: $1,206 · 2023: $1,260 · 2024: $1,174 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.41 | 2019-2025 | |
| Pfizer INC. | $943.50 | 2019-2025 | |
| Amgen INC. | $866.78 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $757.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $687.83 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $571.40 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.38 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $294.34 | 2019-2025 | Arexvy, Shingrix, Boostrix |
| Astellas Pharma US INC | $283.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.88 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $243.14 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Kowa Pharmaceuticals America, INC. | $221.48 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $183.81 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.52 | 2019-2024 | Capvaxive |
| Amarin Pharma, INC. | $131.75 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $128.58 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $126.28 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $116.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $115.88 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $114.87 | 2019-2023 | Camzyos |
| Abbott Laboratories | $113.91 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Takeda Pharmaceuticals U.S.A., INC. | $83.87 | 2019-2024 | Trintellix |
| Esperion Therapeutics, INC. | $79.59 | 2020-2024 | Nexletol |
| Boston Scientific Corporation | $73.20 | 2022-2025 | Watchman Flx |
| Exact Sciences Corporation | $43.62 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $33.96 | 2023 | Yupelri |
| Corcept Therapeutics | $30.59 | 2022-2025 | Korlym |
| Davol INC. | $25.88 | 2021 | |
| Shire North American Group INC | $25.35 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.94 | 2019-2020 | |
| Biogen, INC. | $19.55 | 2021 | |
| Medtronic, INC. | $16.58 | 2022 | |
| Seqirus USA INC | $15.98 | 2025 | Fluad, Flucelvax |
| Biohaven Pharmaceuticals, INC. | $14.81 | 2021 | |
| Shield Therapeutics INC | $14.50 | 2024 | |
| Paratek Pharmaceuticals, INC. | $13.85 | 2021 | |
| Bausch Health US, LLC | $13.64 | 2021 | |
| Dexcom, INC. | $13.56 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Gilliland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.